The Board of Directors approved the financial statements and auditor's reports for the fiscal year ended December 31, 2025.
Two capital reduction measures were approved for presentation to the Extraordinary General Assembly: the cancellation of all treasury shares and a reduction in the nominal value of shares from USD 0.70 to USD 0.40 to offset losses.
The Board authorized convening both the Ordinary and Extraordinary General Assemblies to approve the capital reductions and an extension of the company's term for 25 years.
Approved multiple regulatory and governance reports for 2025, including AML/CFT activities, internal control procedures, and ESG sustainability disclosures.